Alcohol: The Most Widely Used Drug in America, Explained
Legal, ubiquitous, underestimated. 105,400 alcohol-induced deaths in 2022 and a medication most clinicians still don't prescribe.
Body — 8 lenses: [Science: GABA-A positive allosteric modulator, NMDA antagonist, multiple neurotransmitter effects. Biology: dose-dependent CNS depression; acute risks (respiratory depression, injury, aspiration); chronic (hepatic, cardiovascular, cancer risk across 7 cancers per 2025 Surgeon General report, wernicke-korsakoff). Psychology: withdrawal can be fatal (seizures, DTs); craving neurobiology. Policy: age 21, OSHA workplace, ABC licensing, dram shop. Trends: 105,400 alcohol-induced deaths in 2022 — 30% pandemic-era surge. Social: sober-curious movement, NA beer boom, cultural normalization + medical reframing. Treatment: FDA-approved meds (naltrexone, acamprosate, disulfiram) — underused; only ~10% of AUD gets treatment. Motivational interviewing + CBT + 12-step. Harm reduction: managed drinking, eating+hydration, avoiding mixing with benzos/opioids, medically-managed withdrawal when needed.]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Continue reading
More from this section
The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.
Science & MedicineFrance Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.
France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.
Science & MedicineThe FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.
DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.